- The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Roche's (OTCQX:RHHBY) Rozlytrek (entrectinib) for the treatment of patients with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion or patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
- A final decision from the European Commission usually takes ~60 days.
European advisory group backs Roche's entrectinib
Recommended For You
More Trending News
About RHHBY Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RHHBY | - | - |
Roche Holding AG |